<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00604201</url>
  </required_header>
  <id_info>
    <org_study_id>080046</org_study_id>
    <secondary_id>08-H-0046</secondary_id>
    <nct_id>NCT00604201</nct_id>
    <nct_alias>NCT00608413</nct_alias>
  </id_info>
  <brief_title>Stem Cell Transplant Using Peripheral and Cord Blood Stem Cells to Treat Severe Aplastic Anemia and Myelodysplastic Syndrome</brief_title>
  <official_title>Co-Infusion of Umbilical Cord Blood and Haploidentical CD34+ Cells Following Nonmyeloablative Conditioning as Treatment for Severe Aplastic Anemia and MDS Associated With Severe Neutropenia Refractory to Immunosuppressive Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and effectiveness of treating patients with severe&#xD;
      aplastic anemia (SAA) or myelodysplastic syndrome (MDS) with both peripheral blood stem cells&#xD;
      from a family member and umbilical cord blood stem cells from an unrelated donor.&#xD;
&#xD;
      Patients with SAA or MDS for whom other treatments have failed or are not available may be&#xD;
      eligible for this study. Candidates may not have a tissue-matched sibling or matched&#xD;
      unrelated donor and must have a family member who is a partial tissue type match.&#xD;
&#xD;
      Participants undergo the following tests and procedures:&#xD;
&#xD;
        -  Insertion of a central intravenous (IV) line (plastic tube) into a large vein. The tube&#xD;
           is used for giving the donated stem cells and antibiotics and other medicines, for&#xD;
           transfusions of red blood cells and platelets, and for collecting blood samples.&#xD;
&#xD;
        -  Preparatory chemotherapy (fludarabine, cyclophosphamide and anti-thymocyte globulin) and&#xD;
           total body irradiation to suppress immunity and prevent rejection of the donated cells.&#xD;
&#xD;
        -  Infusion of the donated stem cells and umbilical cord cells.&#xD;
&#xD;
        -  Immune suppression with the drugs tacrolimus, mycophenolate mofetil and prednisone to&#xD;
           prevent rejection of the donated cells and to prevent graft-versus-host disease (GVHD),&#xD;
           a complication of stem cell transplants in which the donors immune cells destroy the&#xD;
           patients healthy tissues.&#xD;
&#xD;
      The average hospital stay after stem cell transplantation is 3 to 4 weeks. Patients return&#xD;
      for frequent follow-up visits for the first 2 to 4 months after transplantation. Once the&#xD;
      patient returns home, his or her referring physician is asked to send results of any&#xD;
      laboratory testing to the NIH researchers at least every 3 months for the first 3 years and&#xD;
      annually thereafter. Patient follow-up visits are scheduled at NIH at 1, 2, 3, 4 and 5 years&#xD;
      after transplantation to monitor for signs of disease or post-transplantation complications,&#xD;
      such as infection or GVHD. After 5 years, participants are offered the opportunity to enroll&#xD;
      in NHLBIs long-term evaluation and follow-up care protocol.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Severe aplastic anemia (SAA) and myelodysplastic syndrome (MDS) are life-threatening bone&#xD;
      marrow disorders. For SAA patients, long term survival can be achieved with immunosuppressive&#xD;
      treatment. However, of those patients treated with immunosuppressive therapy, one quarter to&#xD;
      one third will not respond, and about 50 percent of responders will relapse.&#xD;
&#xD;
      Allogeneic bone marrow transplantation from either HLA-matched sibling or matched unrelated&#xD;
      donor cures about 70 percent of patients with SAA and 30-60 percent of patients with MDS.&#xD;
      Unfortunately, most patients with these disorders are not suitable candidates for&#xD;
      hematopoietic stem cell transplantation (HSCT) due to advanced age or lack of a&#xD;
      histocompatible donor. For such patients, transplantation using unrelated cord blood (UCB)&#xD;
      has been shown to be a reasonable alternative transplant strategy. The advantage to UCB&#xD;
      transplant is the ease and rapidity of availability, requirement of less than perfect HLA&#xD;
      match, and lower rates of graft versus host disease compared to mismatched bone marrow or&#xD;
      peripheral blood stem cell transplants. The major disadvantage of UCB transplantation in&#xD;
      adults is the limited number of nucleated cells contained within the cord unit resulting in&#xD;
      prolonged neutropenia and failure of engraftment which contributes to infection and&#xD;
      transplant related mortality (TRM). In order to harness the advantage of UCB availability and&#xD;
      to overcome the disadvantage of delayed neutrophil recovery, we propose to test whether&#xD;
      co-administration of unrelated umbilical cord blood and a relatively low number of highly&#xD;
      purified haploidentical peripheral blood CD34+ cells from a related donor might promote rapid&#xD;
      engraftment and reduce TRM secondary to prolonged neutropenia associated with conventional&#xD;
      umbilical cord blood transplant (UCBT).&#xD;
&#xD;
      This research protocol is therefore designed to evaluate the safety and effectiveness of&#xD;
      co-infusion of unrelated umbilical cord blood and haploidentical CD34 plus cells from a&#xD;
      related donor following nonmyeloablative conditioning for neutropenic patients with SAA or&#xD;
      MDS with refractory anemia (RA) that has proven to be refractory to medical therapy. Subjects&#xD;
      will receive a novel non-myeloablative immunosuppressive conditioning regimen of&#xD;
      cyclophosphamide, fludarabine, horse ATG (antithymocyte globulin) and one dose of total body&#xD;
      irradiation (200cGy) followed by an infusion of the allografts. The haploidentical stem cell&#xD;
      product will be T-cell depleted and enriched for CD34 plus cells using the Miltenyi CliniMacs&#xD;
      system. To reduce TRM secondary to prolonged neutropenia associated with conventional UCB&#xD;
      transplantation, haploidentical CD34+ stem cells will be co-infused with a single UCB unit&#xD;
      (serologically matched at greater than or equal to 4/6 HLA loci).&#xD;
&#xD;
      The primary endpoint is donor engraftment by day 42 (defined as an ANC of greater than 500&#xD;
      from either the haplo donor, the cord, or both combined). Secondary endpoints will include&#xD;
      standard transplant outcome variables such as non-hematological toxicities, incidence and&#xD;
      severity of acute and chronic GVHD, and relapse of disease. We will also evaluate ANC&#xD;
      recovery (ANC greater than 500 cells/microl) at day 22, and 100 day and 200 day treatment&#xD;
      related mortality (TRM) of this novel transplant approach. Health related quality of life&#xD;
      will also be assessed pre-transplant 30 and 100 days post-transplant, and every 6 months&#xD;
      until 5 years post transplant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 21, 2008</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Actual">October 25, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Engrafted by Day 42</measure>
    <time_frame>42 days</time_frame>
    <description>Participants who reached engraftment by day 42 (±3 days) defined as an absolute neutrophil count (ANC) of U&gt; U500 cells/µl</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Developed Chronic GVHD</measure>
    <time_frame>5 years</time_frame>
    <description>Participants who developed chronic graft-versus-host disease (GVHD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Developed Acute GVHD</measure>
    <time_frame>100 days</time_frame>
    <description>Participants who had acute graft-versus-host disease (GVHD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced Treatment Related Mortality (TRM) Day 100</measure>
    <time_frame>100 days</time_frame>
    <description>Number of participants who experienced treatment related mortality (TRM) by day 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced Treatment Related Mortality (TRM) Day 200</measure>
    <time_frame>200 days</time_frame>
    <description>Number of participants who experienced treatment related mortality (TRM) by day 200</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Had ANC Recovery at Day 22</measure>
    <time_frame>22 days</time_frame>
    <description>Number of participants who reached engraftment by day 22 (±3 days) defined as an ANC of U&gt; U500 cells/µl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Had Relapse of Disease</measure>
    <time_frame>5 years</time_frame>
    <description>Participants who had experienced relapse of disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Developed Grade II Acute GVHD</measure>
    <time_frame>100 days</time_frame>
    <description>Participants who developed Grade II Acute GVHD as defined by CIMBTR criteria for Organ Stages of Acute GVHD.&#xD;
Stage II Acute GVHD: Skin - rash on 25-50 percent body surface area; Liver - Total Bilirubin 3.1-6.0 mg/dL; Lower GI - Diarrhea 1001-1500 mL/day.&#xD;
Grade I GVHD is characterized as mild disease, grade II GVHD as moderate, grade III as severe, and grade IV life-threatening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Developed Grade III Acute GVHD</measure>
    <time_frame>100 days</time_frame>
    <description>Participants who developed Grade III Acute GVHD as defined by CIMBTR criteria for Organ Stages of Acute GVHD.&#xD;
Stage III Acute GVHD: Skin - Rash on &gt;50% of body surface; Liver - Total Bilirubin 6.1 - 15.0 mg/dL; Lower GI - Diarrhea &gt; 1500 mL/day&#xD;
Grade I GVHD is characterized as mild disease, grade II GVHD as moderate, grade III as severe, and grade IV life-threatening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Developed Mild Chronic GVHD</measure>
    <time_frame>5 years</time_frame>
    <description>Participants who developed mild chronic graft vs host disease (GVHD).&#xD;
Mild chronic GVHD is 2 or fewer organs with no more than score 1 and no lung involvement. Mild disease is associated with a good prognosis whereas severe disease is associated with higher treatment-related mortality and lower survival.&#xD;
Organs are scored on a 0 to 3 scale from no involvement/no symptoms to severe functional compromise.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Developed Moderate Chronic GVHD</measure>
    <time_frame>5 years</time_frame>
    <description>Participants who experienced moderate chronic GVHD.&#xD;
Moderate GVHD is 3 or more organs with score 1, any organ with score 2, or lung with score 1, and usually requires systemic immune-suppressive treatment. Mild disease is associated with a good prognosis whereas severe disease is associated with higher treatment-related mortality and lower survival.&#xD;
Organs are scored on a 0 to 3 scale from no involvement/no symptoms to severe functional compromise.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Developed Severe Chronic GVHD</measure>
    <time_frame>5 years</time_frame>
    <description>Participants who developed severe chronic GVHD.&#xD;
Severe chronic GVHD is any organ with a score of 3 or lung with a score of 2, and means that substantial organ damage already exists. Mild disease is associated with a good prognosis whereas severe disease is associated with higher treatment-related mortality and lower survival&#xD;
Organs are scored on a 0 to 3 scale from no involvement/no symptoms to severe functional compromise.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Developed Steroid Refractory Acute GVHD</measure>
    <time_frame>100 days</time_frame>
    <description>Participants who had developed steroid refractory (not responding to standard steroid therapy) acute GVHD.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Myelodysplastic Syndrome (MDS) With Refractory Anemia (RA)</condition>
  <condition>Severe Aplastic Anemia (SAA)</condition>
  <arm_group>
    <arm_group_label>Co-infusion of UCB and Haploidentical CD34+ cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stem cell recipients received co-infusion of unrelated umbilical cord blood (UCB) and haploidentical CD34+ cells from a related donor following non-myeloablative conditioning for neutropenic patients with severe aplastic anemia (SAA) or myelodysplastic syndrome (MDS) with refractory anemia (RA)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Umbilical Cord Blood</intervention_name>
    <description>unrelated umbilical cord blood will be co-infused with haploidentical CD34-selected cells from a related donor for treatment of severe aplastic anemia and myelodysplastic syndrome.</description>
    <arm_group_label>Co-infusion of UCB and Haploidentical CD34+ cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA - RECIPIENT:&#xD;
&#xD;
          -  Diagnosed with severe aplastic anemia characterized by all of the following:&#xD;
&#xD;
               1. Bone marrow cellularity less than 30 percent (excluding lymphocytes)&#xD;
&#xD;
               2. Transfusion dependence for platelets and/or red blood cells (RBCs)&#xD;
&#xD;
               3. Neutropenia (absolute neutrophil count less than 500 cells/microL) OR for&#xD;
                  patients receiving granulocyte transfusions, absolute neutrophil count &lt; 500&#xD;
                  cells/microL before beginning granulocyte transfusions].)&#xD;
&#xD;
        OR&#xD;
&#xD;
          -  Diagnosed with myelodysplastic syndrome characterized by refractory anemia OR&#xD;
             refractory anemia with ringed sideroblasts (RARS and at least one of the following:&#xD;
&#xD;
               1. Neutropenia [(absolute neutrophil count &lt; 500 cells/microL) OR for patients&#xD;
                  receiving granulocyte transfusions, absolute neutrophil count &lt; 500 cells/microL&#xD;
                  before beginning granulocyte transfusions]) and history of 1 or more&#xD;
                  opportunistic infections related to neutropenia. OR&#xD;
&#xD;
               2. History of severe aplastic anemia transformed to MDS&#xD;
&#xD;
          -  Intolerance of or failure to respond standard immunosuppressive therapy.&#xD;
&#xD;
          -  Availability of at least one HLA-haploidentical (i.e. greater than or equal to 5/10&#xD;
             and less than or equal to 8/10 HLA match) related donor (HLA-A, B, C, DR, and DO loci)&#xD;
             who is available to donate CD34+ cells (4-75 years old).&#xD;
&#xD;
          -  Availability of at least one 4/6 HLA-matched (HLA-A, B, and DR loci) cord blood unit&#xD;
             from the National Marrow Donor Program (NMDP). The cord blood unit must contain a&#xD;
             minimum total nucleated cells (TNC) (prior to thawing) of at least 1.5 x 10(7) cells&#xD;
             per kilogram of recipient body weight with the following exception: if the minimum&#xD;
             criterion of TNC is not met the cord unit must contain at least 1.7 x 10(5) CD34 plus&#xD;
             cells/kg (prior to thawing).&#xD;
&#xD;
          -  Ages 4-55 years inclusive.&#xD;
&#xD;
          -  Ability to comprehend the investigational nature of the study and provide informed&#xD;
             consent. The procedure will be explained to subjects aged 4-17 years with formal&#xD;
             consent being obtained from parents or legal guardian.&#xD;
&#xD;
               -  Telomere Length Testing&#xD;
&#xD;
               -  In patients where a suspicion for a familial bone marrow failure syndromes (BMFS)&#xD;
                  exists, TERC and TERT mutation testing will be performed on protocol 04-H-0012 or&#xD;
                  performed elsewhere prior to enrolling on 04-H-0012.&#xD;
&#xD;
        EXCLUSION CRITERIA - RECIPIENT:&#xD;
&#xD;
          -  Availability of an HLA identical or 9/10 HLA matched(HLA A, B, C, DR, and DO&#xD;
             loci-relative to serve as a stem cell donor.&#xD;
&#xD;
          -  The patient is deemed to be a candidate for a 6/6 HLA matched unrelated stem cell&#xD;
             transplant (availability of a donor and resources required for such a transplant).&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 2 or more.&#xD;
&#xD;
          -  Major anticipated illness or organ failure incompatible with survival from transplant&#xD;
&#xD;
          -  Severe psychiatric illness. Mental deficiency sufficiently severe as to make&#xD;
             compliance with the transplant treatment unlikely and making informed consent&#xD;
             impossible.&#xD;
&#xD;
          -  Positive pregnancy test for women of childbearing age.&#xD;
&#xD;
          -  HIV positive&#xD;
&#xD;
          -  Diagnosis of Fanconi anemia (by chromosome breakage study).&#xD;
&#xD;
          -  Diffusion capacity of carbon monoxide (DLCO) less than 40 percent using DLCO corrected&#xD;
             for Hgb or lung volumes (patients under the age of 10 may be excluded from this&#xD;
             criterion if they have difficulty performing the test correctly and thus are unable to&#xD;
             have their DLCO assessed) using DL Adj and DL/VA/Adj.&#xD;
&#xD;
          -  Left ventricular ejection fraction less than 40 percent (evaluated by ECHO)&#xD;
&#xD;
          -  Transaminases greater than 5x upper limit of normal (when transaminases are elevated,&#xD;
             the subject may be excluded at the discretion of the PI).&#xD;
&#xD;
          -  Serum bilirubin greater than 4 mg/dl&#xD;
&#xD;
          -  Creatinine clearance less than 50 cc/min by 24 hr urine collection (adjusted for body&#xD;
             surface area, i.e.50 ml/min/1.73m(2))&#xD;
&#xD;
          -  Serum creatinine &gt; 2.5 mg/dl&#xD;
&#xD;
          -  Failure to collect an adequate number of CD34+ cells (i.e. greater than or equal 2 x&#xD;
             10(6) CD34+ cells/kg) for transplantation from the subject s haploidentical relative.&#xD;
&#xD;
          -  Presence of an active infection not adequately responding to appropriate therapy&#xD;
&#xD;
          -  History of a malignant disease liable to relapse or progress within 5 years&#xD;
&#xD;
        INCLUSION CRITERIA - RELATED HAPLOIDENTICAL DONOR DONATING PURIFIED CD34 PLUS CELLS:&#xD;
&#xD;
          -  HLA mismatched family donor (greater than or equal to 5/10 and less than or equal to&#xD;
             8/10 HLA matched (HLA-A, B, C, DR and DO loci) who is available to donate CD34+ cells.&#xD;
&#xD;
          -  Ages 4-75 inclusive&#xD;
&#xD;
          -  Weight greater than or equal to 15 kg.&#xD;
&#xD;
          -  For adults: Ability to comprehend the investigational nature of the study and provide&#xD;
             informed consent. For minors: Written informed consent from one parent or guardian who&#xD;
             is not the recipient of the transplant and informed assent: The process will be&#xD;
             explained to the minor on a level of complexity appropriate for their age and ability&#xD;
             to comprehend.&#xD;
&#xD;
          -  If there is a suspicion of familial BMFS in the recipient, then the donor must have&#xD;
             undergone genetic testing for genes associated with BMFS - performed at a&#xD;
             CLIA-certified laboratory, prior to enrolling in this protocol.&#xD;
&#xD;
        EXCLUSION CRITERIA RELATED DONOR (ANY OF THE FOLLOWING):&#xD;
&#xD;
          -  Pregnant or breastfeeding.&#xD;
&#xD;
          -  A suitable adult haplo identical donor is available.&#xD;
&#xD;
          -  Unfit to receive filgrastim (G-CSF) and undergo apheresis (history of stroke, MI,&#xD;
             unstable angina, uncontrolled hypertension, severe heart disease or palpable spleen).&#xD;
&#xD;
          -  HIV positive (Donors who are positive for HBV, HCV or HTLV I/II, T. cruzi [Chagas] may&#xD;
             be used at the discretion of the investigator following counseling and approval from&#xD;
             the recipient).&#xD;
&#xD;
          -  Sickling hemoglobinopathies including HbSS, HbAS, HbSC. Donors with HbAS are&#xD;
             acceptable.&#xD;
&#xD;
          -  Severe psychiatric illness. Mental deficiency sufficiently severe as to make&#xD;
             compliance with the BMT treatment unlikely and making informed consent impossible.&#xD;
&#xD;
          -  Screening test positive for Chagas disease (Trypanosoma cruzi /T.&#xD;
             cruzi/trypanosomiasis) confirmed by the Center for Disease Control (CDC).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard W Childs, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Heart, Lung, and Blood Institute (NHLBI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2008-H-0046.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Young NS, Barrett AJ. The treatment of severe acquired aplastic anemia. Blood. 1995 Jun 15;85(12):3367-77. Review.</citation>
    <PMID>7780125</PMID>
  </reference>
  <reference>
    <citation>Young NS, Maciejewski J. The pathophysiology of acquired aplastic anemia. N Engl J Med. 1997 May 8;336(19):1365-72. Review.</citation>
    <PMID>9134878</PMID>
  </reference>
  <reference>
    <citation>Zoumbos NC, Gascón P, Djeu JY, Trost SR, Young NS. Circulating activated suppressor T lymphocytes in aplastic anemia. N Engl J Med. 1985 Jan 31;312(5):257-65.</citation>
    <PMID>2981406</PMID>
  </reference>
  <verification_date>April 7, 2020</verification_date>
  <study_first_submitted>January 8, 2008</study_first_submitted>
  <study_first_submitted_qc>January 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2008</study_first_posted>
  <results_first_submitted>July 13, 2020</results_first_submitted>
  <results_first_submitted_qc>July 13, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 31, 2020</results_first_posted>
  <last_update_submitted>September 18, 2020</last_update_submitted>
  <last_update_submitted_qc>September 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nonmyeloablative</keyword>
  <keyword>Haploidentical</keyword>
  <keyword>Umbilical Cord Blood</keyword>
  <keyword>SAA</keyword>
  <keyword>Severe Aplastic Anemia</keyword>
  <keyword>Myelodysplastic Syndrome</keyword>
  <keyword>MDS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
    <mesh_term>Anemia, Refractory</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 13, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/01/NCT00604201/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Co-infusion of UCB and Haploidentical CD34+ Cells</title>
          <description>Stem cell recipients received co-infusion of unrelated umbilical cord blood (UCB) and haploidentical CD34+ cells from a related donor following non-myeloablative conditioning for neutropenic patients with severe aplastic anemia (SAA) or myelodysplastic syndrome (MDS) with refractory anemia (RA)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Co-infusion of UCB and Haploidentical CD34+ Cells</title>
          <description>Stem cell recipients received co-infusion of unrelated umbilical cord blood (UCB) and haploidentical CD34+ cells from a related donor following non-myeloablative conditioning for neutropenic patients with severe aplastic anemia (SAA) or myelodysplastic syndrome (MDS) with refractory anemia (RA)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Developed Chronic GVHD</title>
        <description>Participants who developed chronic graft-versus-host disease (GVHD)</description>
        <time_frame>5 years</time_frame>
        <population>All recipients that received unrelated umbilical cord blood (UCB) and haploidentical CD34+ cells</population>
        <group_list>
          <group group_id="O1">
            <title>Co-infusion of UCB and Haploidentical CD34+ Cells</title>
            <description>Stem cell recipients received co-infusion of unrelated umbilical cord blood (UCB) and haploidentical CD34+ cells from a related donor following non-myeloablative conditioning for neutropenic patients with severe aplastic anemia (SAA) or myelodysplastic syndrome (MDS) with refractory anemia (RA)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Developed Chronic GVHD</title>
          <description>Participants who developed chronic graft-versus-host disease (GVHD)</description>
          <population>All recipients that received unrelated umbilical cord blood (UCB) and haploidentical CD34+ cells</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Developed Acute GVHD</title>
        <description>Participants who had acute graft-versus-host disease (GVHD)</description>
        <time_frame>100 days</time_frame>
        <population>All recipients that received unrelated umbilical cord blood (UCB) and haploidentical CD34+ cells</population>
        <group_list>
          <group group_id="O1">
            <title>Co-infusion of UCB and Haploidentical CD34+ Cells</title>
            <description>Stem cell recipients received co-infusion of unrelated umbilical cord blood (UCB) and haploidentical CD34+ cells from a related donor following non-myeloablative conditioning for neutropenic patients with severe aplastic anemia (SAA) or myelodysplastic syndrome (MDS) with refractory anemia (RA)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Developed Acute GVHD</title>
          <description>Participants who had acute graft-versus-host disease (GVHD)</description>
          <population>All recipients that received unrelated umbilical cord blood (UCB) and haploidentical CD34+ cells</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Engrafted by Day 42</title>
        <description>Participants who reached engraftment by day 42 (±3 days) defined as an absolute neutrophil count (ANC) of U&gt; U500 cells/µl</description>
        <time_frame>42 days</time_frame>
        <population>All recipients that received unrelated umbilical cord blood (UCB) and haploidentical CD34+ cells</population>
        <group_list>
          <group group_id="O1">
            <title>Co-infusion of UCB and Haploidentical CD34+ Cells</title>
            <description>Stem cell recipients received co-infusion of unrelated umbilical cord blood (UCB) and haploidentical CD34+ cells from a related donor following non-myeloablative conditioning for neutropenic patients with severe aplastic anemia (SAA) or myelodysplastic syndrome (MDS) with refractory anemia (RA)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Engrafted by Day 42</title>
          <description>Participants who reached engraftment by day 42 (±3 days) defined as an absolute neutrophil count (ANC) of U&gt; U500 cells/µl</description>
          <population>All recipients that received unrelated umbilical cord blood (UCB) and haploidentical CD34+ cells</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced Treatment Related Mortality (TRM) Day 100</title>
        <description>Number of participants who experienced treatment related mortality (TRM) by day 100</description>
        <time_frame>100 days</time_frame>
        <population>All recipients that received unrelated umbilical cord blood (UCB) and haploidentical CD34+ cells</population>
        <group_list>
          <group group_id="O1">
            <title>Co-infusion of UCB and Haploidentical CD34+ Cells</title>
            <description>Stem cell recipients received co-infusion of unrelated umbilical cord blood (UCB) and haploidentical CD34+ cells from a related donor following non-myeloablative conditioning for neutropenic patients with severe aplastic anemia (SAA) or myelodysplastic syndrome (MDS) with refractory anemia (RA)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Treatment Related Mortality (TRM) Day 100</title>
          <description>Number of participants who experienced treatment related mortality (TRM) by day 100</description>
          <population>All recipients that received unrelated umbilical cord blood (UCB) and haploidentical CD34+ cells</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced Treatment Related Mortality (TRM) Day 200</title>
        <description>Number of participants who experienced treatment related mortality (TRM) by day 200</description>
        <time_frame>200 days</time_frame>
        <population>All recipients that received unrelated umbilical cord blood (UCB) and haploidentical CD34+ cells</population>
        <group_list>
          <group group_id="O1">
            <title>Co-infusion of UCB and Haploidentical CD34+ Cells</title>
            <description>Stem cell recipients received co-infusion of unrelated umbilical cord blood (UCB) and haploidentical CD34+ cells from a related donor following non-myeloablative conditioning for neutropenic patients with severe aplastic anemia (SAA) or myelodysplastic syndrome (MDS) with refractory anemia (RA)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Treatment Related Mortality (TRM) Day 200</title>
          <description>Number of participants who experienced treatment related mortality (TRM) by day 200</description>
          <population>All recipients that received unrelated umbilical cord blood (UCB) and haploidentical CD34+ cells</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Had ANC Recovery at Day 22</title>
        <description>Number of participants who reached engraftment by day 22 (±3 days) defined as an ANC of U&gt; U500 cells/µl</description>
        <time_frame>22 days</time_frame>
        <population>All recipients that received unrelated umbilical cord blood (UCB) and haploidentical CD34+ cells</population>
        <group_list>
          <group group_id="O1">
            <title>Co-infusion of UCB and Haploidentical CD34+ Cells</title>
            <description>Stem cell recipients received co-infusion of unrelated umbilical cord blood (UCB) and haploidentical CD34+ cells from a related donor following non-myeloablative conditioning for neutropenic patients with severe aplastic anemia (SAA) or myelodysplastic syndrome (MDS) with refractory anemia (RA)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Had ANC Recovery at Day 22</title>
          <description>Number of participants who reached engraftment by day 22 (±3 days) defined as an ANC of U&gt; U500 cells/µl</description>
          <population>All recipients that received unrelated umbilical cord blood (UCB) and haploidentical CD34+ cells</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Had Relapse of Disease</title>
        <description>Participants who had experienced relapse of disease</description>
        <time_frame>5 years</time_frame>
        <population>All recipients that received unrelated umbilical cord blood (UCB) and haploidentical CD34+ cells</population>
        <group_list>
          <group group_id="O1">
            <title>Co-infusion of UCB and Haploidentical CD34+ Cells</title>
            <description>Stem cell recipients received co-infusion of unrelated umbilical cord blood (UCB) and haploidentical CD34+ cells from a related donor following non-myeloablative conditioning for neutropenic patients with severe aplastic anemia (SAA) or myelodysplastic syndrome (MDS) with refractory anemia (RA)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Had Relapse of Disease</title>
          <description>Participants who had experienced relapse of disease</description>
          <population>All recipients that received unrelated umbilical cord blood (UCB) and haploidentical CD34+ cells</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Developed Grade II Acute GVHD</title>
        <description>Participants who developed Grade II Acute GVHD as defined by CIMBTR criteria for Organ Stages of Acute GVHD.&#xD;
Stage II Acute GVHD: Skin - rash on 25-50 percent body surface area; Liver - Total Bilirubin 3.1-6.0 mg/dL; Lower GI - Diarrhea 1001-1500 mL/day.&#xD;
Grade I GVHD is characterized as mild disease, grade II GVHD as moderate, grade III as severe, and grade IV life-threatening.</description>
        <time_frame>100 days</time_frame>
        <population>All recipients that received unrelated umbilical cord blood (UCB) and haploidentical CD34+ cells</population>
        <group_list>
          <group group_id="O1">
            <title>Co-infusion of UCB and Haploidentical CD34+ Cells</title>
            <description>Stem cell recipients received co-infusion of unrelated umbilical cord blood (UCB) and haploidentical CD34+ cells from a related donor following non-myeloablative conditioning for neutropenic patients with severe aplastic anemia (SAA) or myelodysplastic syndrome (MDS) with refractory anemia (RA)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Developed Grade II Acute GVHD</title>
          <description>Participants who developed Grade II Acute GVHD as defined by CIMBTR criteria for Organ Stages of Acute GVHD.&#xD;
Stage II Acute GVHD: Skin - rash on 25-50 percent body surface area; Liver - Total Bilirubin 3.1-6.0 mg/dL; Lower GI - Diarrhea 1001-1500 mL/day.&#xD;
Grade I GVHD is characterized as mild disease, grade II GVHD as moderate, grade III as severe, and grade IV life-threatening.</description>
          <population>All recipients that received unrelated umbilical cord blood (UCB) and haploidentical CD34+ cells</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Developed Grade III Acute GVHD</title>
        <description>Participants who developed Grade III Acute GVHD as defined by CIMBTR criteria for Organ Stages of Acute GVHD.&#xD;
Stage III Acute GVHD: Skin - Rash on &gt;50% of body surface; Liver - Total Bilirubin 6.1 - 15.0 mg/dL; Lower GI - Diarrhea &gt; 1500 mL/day&#xD;
Grade I GVHD is characterized as mild disease, grade II GVHD as moderate, grade III as severe, and grade IV life-threatening.</description>
        <time_frame>100 days</time_frame>
        <population>All recipients that received unrelated umbilical cord blood (UCB) and haploidentical CD34+ cells</population>
        <group_list>
          <group group_id="O1">
            <title>Co-infusion of UCB and Haploidentical CD34+ Cells</title>
            <description>Stem cell recipients received co-infusion of unrelated umbilical cord blood (UCB) and haploidentical CD34+ cells from a related donor following non-myeloablative conditioning for neutropenic patients with severe aplastic anemia (SAA) or myelodysplastic syndrome (MDS) with refractory anemia (RA)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Developed Grade III Acute GVHD</title>
          <description>Participants who developed Grade III Acute GVHD as defined by CIMBTR criteria for Organ Stages of Acute GVHD.&#xD;
Stage III Acute GVHD: Skin - Rash on &gt;50% of body surface; Liver - Total Bilirubin 6.1 - 15.0 mg/dL; Lower GI - Diarrhea &gt; 1500 mL/day&#xD;
Grade I GVHD is characterized as mild disease, grade II GVHD as moderate, grade III as severe, and grade IV life-threatening.</description>
          <population>All recipients that received unrelated umbilical cord blood (UCB) and haploidentical CD34+ cells</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Developed Mild Chronic GVHD</title>
        <description>Participants who developed mild chronic graft vs host disease (GVHD).&#xD;
Mild chronic GVHD is 2 or fewer organs with no more than score 1 and no lung involvement. Mild disease is associated with a good prognosis whereas severe disease is associated with higher treatment-related mortality and lower survival.&#xD;
Organs are scored on a 0 to 3 scale from no involvement/no symptoms to severe functional compromise.</description>
        <time_frame>5 years</time_frame>
        <population>All recipients that received unrelated umbilical cord blood (UCB) and haploidentical CD34+ cells</population>
        <group_list>
          <group group_id="O1">
            <title>Co-infusion of UCB and Haploidentical CD34+ Cells</title>
            <description>Stem cell recipients received co-infusion of unrelated umbilical cord blood (UCB) and haploidentical CD34+ cells from a related donor following non-myeloablative conditioning for neutropenic patients with severe aplastic anemia (SAA) or myelodysplastic syndrome (MDS) with refractory anemia (RA)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Developed Mild Chronic GVHD</title>
          <description>Participants who developed mild chronic graft vs host disease (GVHD).&#xD;
Mild chronic GVHD is 2 or fewer organs with no more than score 1 and no lung involvement. Mild disease is associated with a good prognosis whereas severe disease is associated with higher treatment-related mortality and lower survival.&#xD;
Organs are scored on a 0 to 3 scale from no involvement/no symptoms to severe functional compromise.</description>
          <population>All recipients that received unrelated umbilical cord blood (UCB) and haploidentical CD34+ cells</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Developed Moderate Chronic GVHD</title>
        <description>Participants who experienced moderate chronic GVHD.&#xD;
Moderate GVHD is 3 or more organs with score 1, any organ with score 2, or lung with score 1, and usually requires systemic immune-suppressive treatment. Mild disease is associated with a good prognosis whereas severe disease is associated with higher treatment-related mortality and lower survival.&#xD;
Organs are scored on a 0 to 3 scale from no involvement/no symptoms to severe functional compromise.</description>
        <time_frame>5 years</time_frame>
        <population>All recipients that received unrelated umbilical cord blood (UCB) and haploidentical CD34+ cells</population>
        <group_list>
          <group group_id="O1">
            <title>Co-infusion of UCB and Haploidentical CD34+ Cells</title>
            <description>Stem cell recipients received co-infusion of unrelated umbilical cord blood (UCB) and haploidentical CD34+ cells from a related donor following non-myeloablative conditioning for neutropenic patients with severe aplastic anemia (SAA) or myelodysplastic syndrome (MDS) with refractory anemia (RA)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Developed Moderate Chronic GVHD</title>
          <description>Participants who experienced moderate chronic GVHD.&#xD;
Moderate GVHD is 3 or more organs with score 1, any organ with score 2, or lung with score 1, and usually requires systemic immune-suppressive treatment. Mild disease is associated with a good prognosis whereas severe disease is associated with higher treatment-related mortality and lower survival.&#xD;
Organs are scored on a 0 to 3 scale from no involvement/no symptoms to severe functional compromise.</description>
          <population>All recipients that received unrelated umbilical cord blood (UCB) and haploidentical CD34+ cells</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Developed Severe Chronic GVHD</title>
        <description>Participants who developed severe chronic GVHD.&#xD;
Severe chronic GVHD is any organ with a score of 3 or lung with a score of 2, and means that substantial organ damage already exists. Mild disease is associated with a good prognosis whereas severe disease is associated with higher treatment-related mortality and lower survival&#xD;
Organs are scored on a 0 to 3 scale from no involvement/no symptoms to severe functional compromise.</description>
        <time_frame>5 years</time_frame>
        <population>All recipients that received unrelated umbilical cord blood (UCB) and haploidentical CD34+ cells</population>
        <group_list>
          <group group_id="O1">
            <title>Co-infusion of UCB and Haploidentical CD34+ Cells</title>
            <description>Stem cell recipients received co-infusion of unrelated umbilical cord blood (UCB) and haploidentical CD34+ cells from a related donor following non-myeloablative conditioning for neutropenic patients with severe aplastic anemia (SAA) or myelodysplastic syndrome (MDS) with refractory anemia (RA)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Developed Severe Chronic GVHD</title>
          <description>Participants who developed severe chronic GVHD.&#xD;
Severe chronic GVHD is any organ with a score of 3 or lung with a score of 2, and means that substantial organ damage already exists. Mild disease is associated with a good prognosis whereas severe disease is associated with higher treatment-related mortality and lower survival&#xD;
Organs are scored on a 0 to 3 scale from no involvement/no symptoms to severe functional compromise.</description>
          <population>All recipients that received unrelated umbilical cord blood (UCB) and haploidentical CD34+ cells</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Developed Steroid Refractory Acute GVHD</title>
        <description>Participants who had developed steroid refractory (not responding to standard steroid therapy) acute GVHD.</description>
        <time_frame>100 days</time_frame>
        <population>All recipients that received unrelated umbilical cord blood (UCB) and haploidentical CD34+ cells</population>
        <group_list>
          <group group_id="O1">
            <title>Co-infusion of UCB and Haploidentical CD34+ Cells</title>
            <description>Stem cell recipients received co-infusion of unrelated umbilical cord blood (UCB) and haploidentical CD34+ cells from a related donor following non-myeloablative conditioning for neutropenic patients with severe aplastic anemia (SAA) or myelodysplastic syndrome (MDS) with refractory anemia (RA)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Developed Steroid Refractory Acute GVHD</title>
          <description>Participants who had developed steroid refractory (not responding to standard steroid therapy) acute GVHD.</description>
          <population>All recipients that received unrelated umbilical cord blood (UCB) and haploidentical CD34+ cells</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Co-infusion of UCB and Haploidentical CD34+ Cells</title>
          <description>Stem cell recipients received co-infusion of unrelated umbilical cord blood (UCB) and haploidentical CD34+ cells from a related donor following non-myeloablative conditioning for neutropenic patients with severe aplastic anemia (SAA) or myelodysplastic syndrome (MDS) with refractory anemia (RA)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Epstein-Barr virus associated lymphoproliferative disorder</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Haemolysis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Systolic dysfunction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Scleritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Acute graft versus host disease in intestine</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Chronic graft versus host disease in intestine</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Acute graft versus host disease in intestine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Acute graft versus host disease in liver</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Acute graft versus host disease in skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Chronic graft versus host disease in skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Adenovirus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>BK virus infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Capnocytophaga infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Infection Reactivation, Cytomegalovirus infection</sub_title>
                <counts group_id="E1" events="21" subjects_affected="9" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Encephalitis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Epstein-Barr virus infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Metapneumovirus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pneumonia cytomegaloviral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pneumonia klebsiella</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Posterior reversible encephalopathy syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Toxoplasmosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Varicella zoster virus infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood culture positive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Coronavirus test positive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Stenotrophomonas test positive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Urine electrolytes decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myotonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Posterior reversible encephalopathy syndrome</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pulmonary alveolar haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Exfoliative rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Ingrowing nail</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abdominal injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Dialysis device insertion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Childs, William</name_or_title>
      <organization>National Heart Lung and Blood Institute</organization>
      <phone>+1 301 451 7128</phone>
      <email>childsr@nhlbi.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

